1 |
Barrasa H, Soraluce A, Isla A, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment [J]. J Crit Care, 2019, 50: 69-76.
|
2 |
Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis [J]. Intensive Care Med, 2016, 42(10): 1535-1545.
|
3 |
Boisson M, Mimoz O, Hadzic M, et al. Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients [J]. J Antimicrob Chemother, 2018, 73(10): 2830-2837.
|
4 |
Dayal S, Aluri J, Hall N, et al. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of Lemborexant [J]. Pharmacol Res Perspect, 2021, 9(2): e00758.
|
5 |
US Food and Drug Administration. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis, and impact on dosing and labeling [EB/OL]. [2021-09-20].
|
6 |
China Center for Drug Evaluation. 肝功能损害患者的药代动力学研究技术指导原则--研究设计、数据分析、给药剂量调整和说明书撰写 [EB/OL]. (2019-10-31) [2021-09-20].
|
7 |
Preston RA, Marbury T, Balaratnam G, et al. Pharmacokinetics of Voxelotor in patients with renal and hepatic impairment [J]. J Clin Pharmacol, 2021, 61(4): 493-505.
|
8 |
Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment [J]. Lancet Oncol, 2019, 20(4): e200-e207.
|
9 |
曹运莉, 杜小莉, 朱珠. 肝功能不全时药物剂量调整方法探讨[J]. 中国药师, 2012, 15(4): 549-552.
|
10 |
Gorham J, Taccone FS, Hites M. Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment [J]. Expert Opin Drug Metab Toxicol, 2022, 18(3): 177-187.
|
11 |
Cook AM, Hatton-Kolpek J. Augmented renal clearance [J]. Pharmacotherapy, 2019, 39(3): 346-354.
|
12 |
Mahmoud SH, Shen C. Augmented renal clearance in critical illness: an important consideration in drug dosing [J]. Pharmaceutics, 2017, 9(3): 36.
|
13 |
Luo Y, Wang Y, Ma Y, et al. Augmented renal clearance: what have we known and what will we do? [J]. Front Pharmacol, 2021, 12: 723731.
|
14 |
Chu Y, Luo Y, Ji S, et al. Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance [J]. J Infect Public Health, 2020, 13(1): 68-74.
|
15 |
Chen Y, Liu L, Zhu M. Effect of augmented renal clearance on the therapeutic drug monitoring of vancomycin in patients after neurosurgery [J]. J Int Med Res, 2020, 48(10): 300060520949076.
|
16 |
Chen IH, Nicolau DP. Augmented renal clearance and how to augment antibiotic dosing [J]. Antibiotics (Basel), 2020, 9(7): 393.
|
17 |
黄健, 武阿龙, 徐丙发. 合并低蛋白血症重症患者的抗菌药物给药方案调整研究进展 [J]. 中国新药杂志, 2022, 31(5): 442-447.
|
18 |
Wiedermann CJ. Hypoalbuminemia as surrogate and culprit of infections [J]. Int J Mol Sci, 2021, 22(9): 4496.
|
19 |
Bastida C, Hernández-Tejero M, Cariqueo M, et al. Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections [J]. J Antimicrob Chemother, 2022, 77(5): 1365-1371.
|
20 |
Bartoletti M, Giannella M, Lewis RE, et al. Bloodstream infections in patients with liver cirrhosis [J]. Virulence, 2016, 7(3): 309-319.
|
21 |
Dhanani JA, Ahern B, Lupinsky L, et al. Comparative plasma pharmacokinetics of Ceftriaxone and Ertapenem in normoalbuminemia, hypoalbuminemia, and albumin replacement in a sheep model [J]. Antimicrob Agents Chemother, 2020, 64(7): e02584-19.
|
22 |
Pérez-Blanco JS, Sáez Fernández EM, Calvo MV et al. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach [J]. J Antimicrob Chemother, 2020, 75(8): 2222-2231.
|
23 |
Shekar K, Roberts JA, Welch S, et al. ASAP ECMO: antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: a multi-centre study to optimise drug therapy during ECMO [J]. BMC Anesthesiol, 2012, 12: 29.
|
24 |
Shekar K, Roberts JA, Mcdonald CI, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation [J]. Crit Care, 2012, 16(5): R194.
|
25 |
Shekar K, Roberts JA, Mullany DV, et al. Increased sedation requirements in patients receiving extracorporeal membrane oxygenation for respiratory and cardiorespiratory failure [J]. Anaesth Intensive Care, 2012, 40(4): 648-655.
|
26 |
Ha MA, Sieg AC. Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation [J]. Pharmacotherapy, 2017, 37(2): 221-235.
|
27 |
Cheng V, Abdul-Aziz MH, Roberts JA, et al. Optimising drug dosing in patients receiving extracorporeal membrane oxygenation [J]. J Thorac Dis, 2018, 10(Suppl 5): S629-S641.
|
28 |
Abdul-Aziz MH, Roberts JA. Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter? [J]. Curr Opin Anaesthesiol, 2020, 33(1): 71-82.
|
29 |
Shekar K, Roberts JA, Ghassabian S, et al. Sedation during extracorporeal membrane oxygenation-why more is less [J]. Anaesth Intensive Care, 2012, 40(6): 1067-1069.
|
30 |
Kühn D, Metz C, Seiler F, et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study [J]. Crit Care, 2020, 24(1): 664.
|
31 |
Wang Y, Chen W, Huang Y, et al. Optimized dosing regimens of Meropenem in septic children receiving extracorporeal life support [J]. Front Pharmacol, 2021, 12: 699191.
|
32 |
Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: review of current indications [J]. Transfus Apher Sci, 2019, 58(3): 247-253.
|
33 |
Mahmoud SH, Buhler J, Chu E, et al. Drug dosing in patients undergoing therapeutic plasma exchange [J]. Neurocrit Care, 2021, 34(1): 301-311.
|
34 |
Krzych ŁJ, Czok M, Putowski Z. Is antimicrobial treatment effective during therapeutic plasma exchange? Investigating the role of possible interactions [J]. Pharmaceutics, 2020, 12(5): 395.
|
35 |
Jiang SP, Zhu ZY, Wu XL, et al. Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study [J]. Ther Clin Risk Manag, 2014, 10: 405-412.
|
36 |
Wanden-Berghe C, Patino-Alonso MC, Galindo-Villardón P, et al. Complications associated with enteral nutrition: CAFANE study [J]. Nutrients, 2019, 11(9): 2041.
|
37 |
Williams NT. Medication administration through enteral feeding tubes [J]. Am J Health Syst Pharm, 2008, 65(24): 2347-2357.
|
38 |
中华医学会呼吸病学分会感染学组. 成人抗感染药物下呼吸道局部应用专家共识 [J].中华结核和呼吸杂志, 2021, 44(4): 322-339.
|
39 |
杜光, 赵杰, 卜书红, 等. 雾化吸入疗法合理用药专家共识(2019年版) [J]. 医药导报, 2019, 38(2): 135-146.
|
40 |
施毅. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版) [J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280.
|
41 |
Nau R, Blei C, Eiffert H. Intrathecal antibacterial and antifungal therapies [J]. Clin Microbiol Rev, 2020, 33(3): e00190-19.
|
42 |
中国医师协会神经外科医师分会神经重症专家委员会, 北京医学会神经外科学分会神经外科危重症学组. 神经外科中枢神经系统感染诊治中国专家共识(2021版) [J]. 中华神经外科杂志, 2021, 37(1): 2-15.
|
43 |
Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis [J]. Clin Infect Dis, 2017, 64(6): e34-e65.
|
44 |
No authors listed. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy [J]. Br J Neurosurg, 2000, 14(1): 7-12.
|
45 |
MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation [J]. Int J Antimicrob Agents, 2014, 43(2): 105-113.
|
46 |
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 [J]. Intensive Care Med, 2021, 47(11): 1181-1247.
|